Stockscreener 앱 받기
13.13
3.17%
-0.43
시간 외 거래:
13.13
Neuropace Inc 주식(NPCE)의 최신 뉴스
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company - MarketBeat
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions - Yahoo Finance
NeuroPace, Inc. (NPCE) may report negative earnings: Know the trend ahead of next week's release - MSN
NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen - MarketBeat
NeuroPace falls after setback in trial for neuromodulation system - MSN
Published on: 2026-03-12 04:41:05 - baoquankhu1.vn
NeuroPace at Leerink Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Key Factors Expected to Influence NPCE Stock Performance in 2026 - Bitget
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026 - TradingView
NPCE RNS System Explained: Growth Drivers and Setup for 2026 - TradingView
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand - Yahoo Finance
Neuropace (NPCE) chief medical officer sells $399k in stock - Investing.com Nigeria
Published on: 2026-03-09 06:34:24 - baoquankhu1.vn
NeuroPace appoints Patrick Williams as CFO - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Outlook: Will NeuroPace Inc stock benefit from M AJuly 2025 Technicals & Technical Buy Zone Confirmation - baoquankhu1.vn
NeuroPace (NASDAQ:NPCE) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Rate Cut: Will NeuroPace Inc stock benefit from M AEarnings Recap Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Gains Recap: Is NeuroPace Inc a stock for growth or value investorsJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access - The Globe and Mail
NeuroPace to Present at the Leerink Global Healthcare Conference - Investing News Network
NeuroPace revenue up 24% to USD 26.6M in Q4 2025 - Medical Buyer
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
NeuroPace (NASDAQ:NPCE) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
NeuroPace (NPCE) Loss Narrowing In Q4 Tests Bullish Profitability Narrative - simplywall.st
NeuroPace (NPCE) CMO sells shares under Rule 10b5-1 trading plan - Stock Titan
NeuroPace (NPCE) CEO reports 5,023-share tax-withholding disposition on RSU vesting - Stock Titan
Why NeuroPace Stock Was Inching Higher on Wednesday - AOL.com
Why NeuroPace Stock Was Inching Higher on Wednesday - The Motley Fool
Earnings call transcript: Neuropace beats Q4 2025 EPS forecast, stock dips - Investing.com Australia
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript - The Globe and Mail
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% By Investing.com - Investing.com South Africa
NeuroPace Q4 Earnings Call Highlights - MarketBeat
NeuroPace Beats Q1 Earnings Estimates - National Today
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Neuropace earnings beat by $0.10, revenue topped estimates - Investing.com Canada
NeuroPace : Investor Presentation - marketscreener.com
NeuroPace reports $99.99M revenue, $(0.66) EPS in 10-K - TradingView
NeuroPace Q4 Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
NeuroPace (NASDAQ:NPCE) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
NeuroPace (NPCE) outlines RNS growth, trials and capital moves in 10-K - Stock Titan
NeuroPace Inc.: Fourth Quarter Earnings Overview - Bitget
Neuropace Inc. (NPCE) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Press Release: NeuroPace Reports First Quarter 2025 Financial Results - 富途牛牛
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% - Investing.com Nigeria
NeuroPace Inc.: Q4 Earnings Snapshot - marketscreener.com
NeuroPace (NASDAQ: NPCE) posts 25% 2025 growth and sets 2026 revenue, margin guidance - Stock Titan
Earnings Summary: NeuroPace Q4 - Benzinga
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook - Business Wire
0.85%
1.86%
자본화:
|
볼륨(24시간):